Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADC 1779
- Development stage
- Preclinical
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ADC 1779 is an investigational antibody-drug conjugate (ADC) being developed by Adienne. As an ADC, it is designed to selectively deliver a cytotoxic payload to cells expressing a specific target antigen, thereby maximizing therapeutic efficacy while minimizing systemic toxicity. While the drug is listed in Adienne's development pipeline, specific details regarding its molecular target, payload chemistry, and primary clinical indications have not yet been publicly disclosed by the developer.
- Other names
- ADC 1779-Adienne-ADCADC1779-Adienne-ADCADC-1779-Adienne-ADC
02
Targets
DPP-4 (Dipeptidyl Peptidase-IV)
Beyond the preview
Go deeper on ADC 1779.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADC 1779.